The current status and future directions of myxoma virus, a master in immune evasion
Open Access
- 1 January 2011
- journal article
- review article
- Published by Springer Nature in Veterinary Research
- Vol. 42 (1) , 76
Abstract
Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century.Keywords
This publication has 150 references indexed in Scilit:
- The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeuticsMicrobes and Infection, 2010
- Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusCytokine & Growth Factor Reviews, 2010
- Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cellsLeukemia, 2009
- Myxoma Virus Expressing Interleukin-15 Fails To Cause Lethal Myxomatosis in European RabbitsJournal of Virology, 2009
- M148R and M149R are two virulence factors for myxoma virus pathogenesis in the European rabbitVeterinary Research, 2008
- Interferon-inducible antiviral effectorsNature Reviews Immunology, 2008
- Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenzaVaccine, 2008
- Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7LVirology, 2008
- Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic proteinJournal of General Virology, 2007
- Vaccinia virus N1L protein resembles a B cell lymphoma‐2 (Bcl‐2) family proteinProtein Science, 2007